Drug Profile

RLS 1496

Alternative Names: RLS-1496

Latest Information Update: 19 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rubedo Life Sciences
Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
Mechanism of Action Glutathione peroxidase modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

17 Sep 2025 US FDA approves IND application for RLS 1496 in Actinic keratosis
17 Sep 2025 Rubedo Life Sciences plans a phase Ib/IIa trial for Actinic keratosis in Q4 2025
22 May 2025 Phase-I clinical trials in Plaque psoriasis in Netherlands (Topical)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com